Search

Your search keyword '"Stahl, Maximilian"' showing total 609 results

Search Constraints

Start Over You searched for: Author "Stahl, Maximilian" Remove constraint Author: "Stahl, Maximilian"
609 results on '"Stahl, Maximilian"'

Search Results

1. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes

3. Mapping genotypes to chromatin accessibility profiles in single cells

5. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

7. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

8. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

10. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

12. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

14. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

16. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

17. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms

18. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

20. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

21. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells

23. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.

24. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

25. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

27. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

30. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

32. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

35. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?

36. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years

37. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)

39. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study

41. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Catalog

Books, media, physical & digital resources